search
Back to results

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery

Primary Purpose

Primary Open-angle Glaucoma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
iStent supra
Cataract surgery
Sponsored by
Glaukos Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Open-angle Glaucoma focused on measuring Primary open-angle glaucoma, POAG, Cataract surgery, Suprachoroidal space, Suprachoroidal stent, iStent supra

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild to moderate open-angle glaucoma
  • Characteristics consistent with mild to moderate glaucoma
  • Use of one (1) to three (3) medications at time of screening exam

Exclusion Criteria:

  • Pigmentary or pseudoexfoliative glaucoma
  • Prior incisional glaucoma surgery

Sites / Locations

  • Eye Centers of Racine and Kenosha

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cataract surgery plus iStent supra

Cataract surgery

Arm Description

Outcomes

Primary Outcome Measures

≥ 20% Reduction in Intraocular Pressure (IOP)

Secondary Outcome Measures

Diurnal IOP Reduction from Baseline

Full Information

First Posted
October 25, 2011
Last Updated
May 18, 2022
Sponsor
Glaukos Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT01461278
Brief Title
Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
Official Title
A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
December 22, 2011 (Actual)
Primary Completion Date
March 13, 2019 (Actual)
Study Completion Date
March 12, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Glaukos Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.
Detailed Description
This is an IDE trial to evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 (hereinafter referred to as G3) in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Open-angle Glaucoma
Keywords
Primary open-angle glaucoma, POAG, Cataract surgery, Suprachoroidal space, Suprachoroidal stent, iStent supra

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
505 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cataract surgery plus iStent supra
Arm Type
Experimental
Arm Title
Cataract surgery
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
iStent supra
Intervention Description
Cataract surgery and implantation of one iStent supra
Intervention Type
Procedure
Intervention Name(s)
Cataract surgery
Intervention Description
Cataract surgery alone
Primary Outcome Measure Information:
Title
≥ 20% Reduction in Intraocular Pressure (IOP)
Time Frame
Baseline and Month 24
Secondary Outcome Measure Information:
Title
Diurnal IOP Reduction from Baseline
Time Frame
Baseline and Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mild to moderate open-angle glaucoma Characteristics consistent with mild to moderate glaucoma Use of one (1) to three (3) medications at time of screening exam Exclusion Criteria: Pigmentary or pseudoexfoliative glaucoma Prior incisional glaucoma surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kerry Stephens, O.D.
Organizational Affiliation
Glaukos Corporation
Official's Role
Study Chair
Facility Information:
Facility Name
Eye Centers of Racine and Kenosha
City
Racine
State/Province
Wisconsin
ZIP/Postal Code
53405
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery

We'll reach out to this number within 24 hrs